C
Crispr Therapeutics AG (CRSP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$40.37
-1.87 (-4.43%)
Market Cap: $4.10B
Last updated: Nov 17, 2026 at 11:05 AM ET
Crispr Therapeutics AG (CRSP) Valuation Multiples
Crispr Therapeutics AG (CRSP) trades at 155.2x sales and 2.4x book value. Its P/S of 155.2x is above its 5-year median of 35.5x. Its forward P/E is 23.4x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 23.4x |
| Price to sales | 155.2x |
| Price to book | 2.4x |
| PEG | N/A |
| FCF yield | -9.6% |
Historical Medians
Against its 10-year medians, its P/S is 264.3% above 42.6x and its P/B is 22.6% below 3.1x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 155.2x | 35.5x | 42.6x |
| P/B | 2.4x | 2.4x | 3.1x |
Valuation History
Over the 7 of the 10 year ends shown that have a P/S, its P/S ranged from 6.3x in 2021 to 426.9x in 2018.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $52.44 | N/A | N/A | 2.5x |
| 2024 | $39.36 | N/A | 90.1x | 1.7x |
| 2023 | $62.60 | N/A | 13.5x | 2.7x |
| 2022 | $40.65 | N/A | N/A | 1.7x |
| 2021 | $75.78 | 17.1x | 6.3x | 2.4x |
| 2020 | $153.11 | N/A | N/A | 6.5x |
| 2019 | $60.91 | 62.8x | 11.8x | 3.9x |
| 2018 | $28.57 | N/A | 426.9x | 3.8x |
| 2017 | $23.48 | N/A | 25.5x | 5.7x |
| 2016 | $20.26 | N/A | 52.2x | 3.5x |
Frequently Asked Questions About CRSP
What is CRSP's forward P/E ratio?
Crispr Therapeutics AG has a forward P/E ratio of 23.4x.
What is CRSP's price to sales ratio?
Crispr Therapeutics AG has a price to sales ratio of 155.2x.
CRSP pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors